<i>CYP3A5</i> and <i>CYP3A4</i> , but not <i>ABCB1</i> Polymorphisms Affect Tacrolimus Dose-Adjusted Trough Concentrations in Kidney Transplant Recipients

Abstract

Our results confirm the impact of the CYP3A4*22 allele on TAC pharmacokinetics, as a second significant genetic factor (in addition to the CYP3A5*1 allele) influencing TAC dose-adjusted blood concentrations in kidney transplant recipients.